相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity
Hillel Haim et al.
PLOS PATHOGENS (2011)
Short Communication: High Polymorphism Rates in the HR1 and HR2 gp41 and Presence of Primary Resistance-Related Mutations in HIV Type 1 Circulating in Brazil: Possible Impact on Enfuvirtide Efficacy
Carla Teixeira et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat
Kazuki Izumi et al.
ANTIVIRAL RESEARCH (2010)
A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer
Shi-Hua Xiang et al.
JOURNAL OF VIROLOGY (2010)
Analysis of HIV Type 1 gp41 and Enfuvirtide Susceptibility among Men in the United States Who Were HIV Infected Prior to Availability of HIV Entry Inhibitors
Sarah E. Hudelson et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2009)
HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide
Neelanjana Ray et al.
JOURNAL OF VIROLOGY (2009)
Early Steps of HIV-1 Fusion Define the Sensitivity to Inhibitory Peptides That Block 6-Helix Bundle Formation
Kosuke Miyauchi et al.
PLOS PATHOGENS (2009)
Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
Kristen M. Kahle et al.
PLOS PATHOGENS (2009)
Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure
Xuefang Bai et al.
BIOCHEMISTRY (2008)
Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency
John J. Dwyer et al.
PROTEIN SCIENCE (2008)
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41
Catherine A. Blish et al.
PLOS MEDICINE (2008)
An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations
Emily J. Platt et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K)
Martin Tolstrup et al.
AIDS (2007)
Molecular switch for alternative conformations of the HIV-1V3 region: Implications for phenotype conversion
Osnat Rosen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1
L Pérez-Alvarez et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
JD Reeves et al.
JOURNAL OF VIROLOGY (2005)
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus
EJ Platt et al.
JOURNAL OF VIROLOGY (2005)
Human immunodeficiency virus (HIV) gp41 escape mutants: Cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120
E Desmezieres et al.
JOURNAL OF VIROLOGY (2005)
Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
SW Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp4l and rev-responsive element functions
D Nameki et al.
JOURNAL OF VIROLOGY (2005)
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle
LG Abrahamyan et al.
JOURNAL OF VIROLOGY (2005)
The prolonged culture of human immunodeficiency virus type I in primary lymphocytes increases its sensitivity to neutralization by soluble CD4
P Pugach et al.
VIROLOGY (2004)
α-Complementation assay for HIV envelope glycoprotein-mediated fusion
AU Holland et al.
VIROLOGY (2004)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120
SM Alam et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2004)
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors
SA Gallo et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor
CE Baldwin et al.
JOURNAL OF VIROLOGY (2004)
CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor
W Yuan et al.
JOURNAL OF VIROLOGY (2004)
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity
JD Reeves et al.
JOURNAL OF VIROLOGY (2004)
The HIV Env-mediated fusion reaction
SA Gallo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2003)
Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope
NR Kilgore et al.
JOURNAL OF VIROLOGY (2003)
Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein
MJ Root et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20
VD Trivedi et al.
PROTEIN ENGINEERING (2003)
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation
RM Markosyan et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions
T Koshiba et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites
Y He et al.
JOURNAL OF VIROLOGY (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41
CA Bewley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process
SA Gallo et al.
BIOCHEMISTRY (2001)
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region
DM Eckert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2001)
Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association
AL Maerz et al.
JOURNAL OF VIROLOGY (2001)
Protein design of an HIV-1 entry inhibitor
MJ Root et al.
SCIENCE (2001)
Mode of action of an antiviral peptide from HIV-1 -: Inhibition at a post-lipid mixing stage
Y Kliger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion
GB Melikyan et al.
JOURNAL OF CELL BIOLOGY (2000)
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2000)
Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides
W Shu et al.
BIOCHEMISTRY (2000)
分享论文
